These findings provide a molecular mechanism to support the use of HIF PHD inhibitors in the treatment of diabetic patients with anemia of chronic kidney disease or during hyperoxia in severely premature infants at risk for ROP, a leading cause of childhood blindness. Here, PDC is linked to anemia.